ArticleDrug design, development and therapy2025
Visual Research of Global Orphan Drug from a Bibliometric Perspective.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Challenges and Opportunities in Cronkhite-Canada Syndrome Research: A Bibliometric Analysis Based on the Web of Science Core Collection.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- The impact of China's drug regulatory reform on access to orphan drugs: a cross-sectional study of diseases listed in the rare disease catalog.Frontiers in pharmacology · 2026Article
- Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31 million residents, 2012-2023.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study analyzes the current research landscape and trends in orphan drug development, providing insights for future advancements in the field. Methods: Gathering pertinent material from the China National Knowledge Infrastructure (CNKI) and Web of Science databases. Microsoft Office Excel 2017, VOSview 1.6.20, and CiteSpace 6.3R2 were utilised to summarise the present research state and offer insights into research hotspots in the domain of orphan drugs. Results: A total of 3598 research papers were included, with Chinese research showing a continuous upward trend, while international research has entered a slow development stage. The field of orphan drug research has formed a sizable research team, and cooperation between international institutions is relatively mature. Meanwhile, the United States and the United Kingdom have strong influence in this research field, while China lacks international cooperation. The research focus in this field mainly involves the development and clinical application of orphan drugs, and domestic and foreign research also has its own emphasis. Maintain consistency in clinical trials and medication support for orphan drugs both domestically and internationally; And foreign research has obvious advantages in the development of orphan drugs. Keyword emergence research indicates that the clinical accessibility and regulatory approval of orphan drugs have become a prominent issue of interest both nationally and globally. Conclusion: This study systematically summarises and examines the current research status and emerging trends in the global orphan drug sector by analysing relevant literature from 2000 to 2024 through bibliometric methods. It further delineates the similarities and differences in orphan drug research domestically and internationally, offering valuable references for future investigations in this domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.